232 related articles for article (PubMed ID: 33759024)
21. Utility of Adding SPECT/CT Imaging to Post-Therapeutic Radioiodine Whole-Body Scan in Patients with Differentiated Thyroid Cancer.
Sriprapaporn J; Sethanandha C; Yingsa-nga T; Komoltri C; Thongpraparn T; Harnnanthawiwai C
J Med Assoc Thai; 2015 Jun; 98(6):596-605. PubMed ID: 26219165
[TBL] [Abstract][Full Text] [Related]
22. SPECT/CT imaging in children with papillary thyroid carcinoma.
Kim HY; Gelfand MJ; Sharp SE
Pediatr Radiol; 2011 Aug; 41(8):1008-12. PubMed ID: 21607603
[TBL] [Abstract][Full Text] [Related]
23. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma.
Ruf J; Lehmkuhl L; Bertram H; Sandrock D; Amthauer H; Humplik B; Ludwig Munz D; Felix R
Nucl Med Commun; 2004 Dec; 25(12):1177-82. PubMed ID: 15640775
[TBL] [Abstract][Full Text] [Related]
24. Detection of distant metastasis at the time of ablation in children with differentiated thyroid cancer: the value of pre-ablation stimulated thyroglobulin.
Liu L; Huang F; Liu B; Huang R
J Pediatr Endocrinol Metab; 2018 Jul; 31(7):751-756. PubMed ID: 29953410
[TBL] [Abstract][Full Text] [Related]
25. [Impact of 131I SPECT/CT on the management of differentiated thyroid carcinoma outpatients with radioablation].
Mizokami D; Kosuda S; Shiotani A; Kinoshita F; Saotome K; Morozumi K
Nihon Jibiinkoka Gakkai Kaiho; 2014 May; 117(5):673-80. PubMed ID: 24956745
[TBL] [Abstract][Full Text] [Related]
26. Is postablation whole-body
Liu B; Chen Y; Jiang L; He Y; Huang R; Kuang A
Clin Endocrinol (Oxf); 2017 Jan; 86(1):134-140. PubMed ID: 27434740
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ¹³¹I whole-body imaging, ¹³¹I SPECT/CT, and ¹⁸F-FDG PET/CT in the detection of metastatic thyroid cancer.
Oh JR; Byun BH; Hong SP; Chong A; Kim J; Yoo SW; Kang SR; Kim DY; Song HC; Bom HS; Min JJ
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1459-68. PubMed ID: 21505897
[TBL] [Abstract][Full Text] [Related]
28. Comparative Study of Initial Post-Therapeutic
Dai H; Qi Z; Huang S; Qi M; Huang R
Endocr Pract; 2023 Feb; 29(2):97-103. PubMed ID: 36356838
[TBL] [Abstract][Full Text] [Related]
29. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma.
Wu X; Gu H; Gao Y; Li B; Fan R
Nucl Med Commun; 2018 Jan; 39(1):22-27. PubMed ID: 29135721
[TBL] [Abstract][Full Text] [Related]
31. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
[TBL] [Abstract][Full Text] [Related]
32. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
33. 131I SPECT/CT in the follow-up of patients with differentiated thyroid carcinoma.
Menges M; Uder M; Kuwert T; Schmidt D
Clin Nucl Med; 2012 Jun; 37(6):555-60. PubMed ID: 22614186
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of SPECT/CT for equivocal findings on (131)I whole-body scan in a patient with differentiated papillary thyroid cancer.
Choi B; Kim DH; Son SH; Zeon S; Ahn BC
Clin Nucl Med; 2014 Feb; 39(2):e160-2. PubMed ID: 23531738
[TBL] [Abstract][Full Text] [Related]
35. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
36. [SPECT/CT for staging and treatment monitoring in oncology. Applications in differentiated thyroid cancer and liver tumors].
Weber K; Berger F; Mustafa M; Reiser MF; Bartenstein P; Haug A
Radiologe; 2012 Jul; 52(7):646-52. PubMed ID: 22710988
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer.
Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ
J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706
[TBL] [Abstract][Full Text] [Related]
38. Frequent visualization of thyroglossal duct remnant on post-ablation 131I-SPECT/CT and its clinical implications.
Lee M; Lee YK; Jeon TJ; Chang HS; Kim BW; Lee YS; Park CS; Ryu YH
Clin Radiol; 2015 Jun; 70(6):638-43. PubMed ID: 25824279
[TBL] [Abstract][Full Text] [Related]
39. Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma.
Wong KK; Zarzhevsky N; Cahill JM; Frey KA; Avram AM
Br J Radiol; 2009 Oct; 82(982):860-76. PubMed ID: 19433487
[TBL] [Abstract][Full Text] [Related]
40. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
Rosenbaum-Krumme SJ; Görges R; Bockisch A; Binse I
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
